Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Evaluation of the Antitumor Activity of Dacomitinib in Models of Human Bladder Cancer

Abstract Members of the human epidermal growth factor receptor (HER) family play a significant role in bladder cancer progression and may underlie the development of chemotherapy resistance. Dacomitinib is an irreversible tyrosine kinase inhibitor with structural specificity for the catalytic domain...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Petros D. Grivas, Kathleen C. Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Iya Owainati, Monica Liebert, Lakshmi P. Kunju, Dafydd Thomas, Maha Hussain, Mark L. Day
Format:	Artykuł
Język:	English
Wydane:	BMC 2013-10-01
Seria:	Molecular Medicine
Hasła przedmiotowe:	Dacomitinib Bladder Cancer Xenografts Non-obese Diabetic/severe Combined Immunodeficiency (NOD/SCID) Epidermal Growth Factor Receptor (EGFR) Lapatinib
Dostęp online:	https://doi.org/10.2119/molmed.2013.00108

Podobne zapisy

Efficacy of dacomitinib in patients with EGFR‐mutated NSCLC and brain metastases
od: Jinyao Zhang, i wsp.
Wydane: (2021-12-01)

Virtual screening of Osimertinib and Dacomitinib Analogues with potential activity on EGFR (T790M and l858R Mutations) for non-small cell lung cancer treatment
od: Leydis Luna Torres, i wsp.
Wydane: (2021-10-01)

The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
od: Wen-Chien Cheng, i wsp.
Wydane: (2024-02-01)

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib
od: Jian Liu, i wsp.
Wydane: (2024-01-01)

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer
od: Ji Eun Shin, i wsp.
Wydane: (2025-02-01)

Remarkable response to dacomitinib in a patient with leptomeningeal carcinomatosis due to EGFR‐mutant non‐small cell lung cancer
od: Shun Mizusaki, i wsp.
Wydane: (2021-01-01)

Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
od: Lavacchi D, i wsp.
Wydane: (2019-09-01)

Dacomitinib as a retreatment for advanced non‐small cell lung cancer patient with an uncommon EGFR mutation
od: Ayako Morita, i wsp.
Wydane: (2021-04-01)

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
od: Bo Zhang, i wsp.
Wydane: (2022-03-01)

Case Report: Dacomitinib Overcomes Osimertinib Resistance in NSCLC Patient Harboring L718Q Mutation: A Case Report
od: Qian Shen, i wsp.
Wydane: (2021-12-01)

Bevacizumab plus dacomitinib combination therapy for L858R‐mutated metastatic lung adenocarcinoma: A report of two cases
od: Chi‐Kang Teng, i wsp.
Wydane: (2022-05-01)

Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutation: an ambispective cohort study
od: Xingxiang Pu, i wsp.
Wydane: (2023-10-01)

Pan-EGFR Inhibitor Dacomitinib Resensitizes Paclitaxel and Induces Apoptosis via Elevating Intracellular ROS Levels in Ovarian Cancer SKOV3-TR Cells
od: Ye Jin Lim, i wsp.
Wydane: (2024-01-01)

Case Report: Grade 4 pneumonitis occurred after thoracic radiotherapy and dacomitinib in a patient with lung adenocarcinoma
od: Ailing Liu, i wsp.
Wydane: (2025-02-01)

Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
od: Hsu-Yuan Chen, i wsp.
Wydane: (2024-10-01)

Case Report: Dacomitinib is effective in lung adenocarcinoma with rare EGFR mutation L747P and brain metastases
od: Yibin Li, i wsp.
Wydane: (2022-08-01)

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China
od: Hong-Shuai Li, i wsp.
Wydane: (2022-06-01)

Use of Hu-PBL Mice to Study Pathogenesis of Human-Restricted Viruses
od: Jesús Emanuel Brunetti, i wsp.
Wydane: (2023-01-01)

Recent Developments in NSG and NRG Humanized Mouse Models for Their Use in Viral and Immune Research
od: Maksym Kitsera, i wsp.
Wydane: (2023-02-01)

Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment
od: Hong-Shuai Li, i wsp.
Wydane: (2021-04-01)

Lapatinib-Loaded Nanocapsules Enhances Antitumoral Effect in Human Bladder Cancer Cell
od: Julieti Huch Buss, i wsp.
Wydane: (2019-04-01)

A Novel Quantum Dots-Based Fluorescent Sensor for Determination of the Anticancer Dacomitinib: Application to Dosage Forms
od: Manal A. Alossaimi, i wsp.
Wydane: (2023-03-01)

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios
od: Ikei S. Kobayashi, i wsp.
Wydane: (2021-12-01)

Pristimerin is a Promising Natural Product against Breast Cancer in vitro and in vivo through Apoptosis and the Blockage of Autophagic Flux
od: Buse Cevatemre, i wsp.
Wydane: (2017-11-01)

Clinical efficacy of dacomitinib in rechallenge setting for patients with epidermal growth factor receptor mutant non–small cell lung cancer: A multicenter retrospective analysis (TOPGAN2020‐02)
od: Hisashi Tanaka, i wsp.
Wydane: (2022-05-01)

Synergistic Antitumor Activity and Mechanism of Lapatinib and Paclitaxel in Esophageal Cancer Cells
od: CHEN Tao, i wsp.
Wydane: (2021-01-01)

Establishment and Its Biological Characteristics of Patient-derived Lung Cancer Xenograft Modelse
od: Ying ZHUO, i wsp.
Wydane: (2010-06-01)

Antitumor Efficacy and Mechanisms of Lapatinib in Combination with Cisplatin on Esophageal Squamous Cancer Cells
od: DOU Qiaohua, i wsp.
Wydane: (2019-09-01)

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial
od: Masahiro Iwasaku, i wsp.
Wydane: (2023-07-01)

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations
od: Hong‐Shuai Li, i wsp.
Wydane: (2022-02-01)

A novel pulmonary fibrosis NOD/SCID murine model with natural aging
od: Zhaoxia Ma, i wsp.
Wydane: (2024-09-01)

Establishment of a Spontaneous Liver Fibrosis Model in NOD/SCID Mice Induced by Natural Aging
od: Lihua Qiu, i wsp.
Wydane: (2023-12-01)

Drug-induced liver injury associated with dacomitinib: A case report
od: Xuanxuan Wang, i wsp.
Wydane: (2022-09-01)

Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review
od: Hui Zhang, i wsp.
Wydane: (2022-04-01)

The development and improvement of immunodeficient mice and humanized immune system mouse models
od: Jiaxuan Chen, i wsp.
Wydane: (2022-10-01)

Immune deficiency phenotypes of Il2rg, Rag2 or Il2rg/Rag2 double knockout rats; establishment of human leukemia xenograft models
od: Joo-Il Kim, i wsp.
Wydane: (2024-12-01)

Effects of Muse Cell on a Mouse Model With Acute Encephalopathy
od: Tatsuya Kawaguchi, i wsp.
Wydane: (2025-01-01)

Thonzonium bromide inhibits progression of malignant pleural mesothelioma through regulation of ERK1/2 and p38 pathways and mitochondrial uncoupling
od: Irene Dell’Anno, i wsp.
Wydane: (2024-06-01)

Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review
od: Guangjian Yang, i wsp.
Wydane: (2024-05-01)

Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer
od: Freeman Daniel J, i wsp.
Wydane: (2012-07-01)